People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Repair Biotechnologies, Inc. | — | Biotechnology | Series A | $25.5M | $14.3M | 2023 |
| Lento Bio, Inc | — | Pharmaceuticals | Series A | $5.0M | $42.0M | 2023 |
| Lysoclear, Inc. | — | Pharmaceuticals | Seed | $3.0M | $114.1M | 2018 |
| Antoxerene, Inc. | — | Biotechnology | Seed | $1.1M | $48.8M | 2017 |
Kelsey Moody at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kelsey Moody on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Roger Bagg | 2 | 2 |
| Aaron Wolfe | 1 | 3 |
| KENNETH SCOTT | 1 | 2 |
| Guilherme Cherman Perdigao De Oliveira | 1 | 1 |
| Reason N/A | 1 | 1 |
| Guilherme Cherman Perdig?o De Oliveira | 1 | 1 |
| Anthony Matthew Chow | 1 | 1 |
| Kris Barnes | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.